Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.

Thompson RG, Peterson J, Gottlieb A, Mullane J

Diabetes1 Apr 1997Cited by 53 (Europe PMC)

PMID9075803DOI10.2337/diab.46.4.632PepBankPUB-09075803

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide reduced the test-meal plasma glucose response versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced blood glucose after the test meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTest-meal plasma glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg q.i.d. · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 microg pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580301
02HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide reduced the test-meal plasma glucose response versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced blood glucose after the test meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTest-meal plasma glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg q.i.d. · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 microg pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580302
03HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide reduced the test-meal plasma glucose response versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced blood glucose after the test meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTest-meal plasma glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 microg q.i.d. · subcutaneous · 1 weekAs given in this study (human).
Source sentences
Summary
The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 microg pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580303
04HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide reduced the test-meal plasma glucose response versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced blood glucose after the test meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTest-meal plasma glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 microg q.i.d. · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 microg pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580304
05HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide reduced mean daily plasma glucose versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced average daily blood glucose compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMean 24-h plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg q.i.d. · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
In addition, 24-h mean plasma glucose concentrations were significantly lowered in patients receiving 30 microg of pramlintide for 2 weeks compared with placebo, while the 100-microg pramlintide dose did not reach statistical significance for the 24-h glucose profiles.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580305
06HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide did not significantly lower mean daily glucose versus placebo.
In plain wordsIn patients with IDDM, pramlintide did not significantly lower average daily blood glucose compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMean 24-h plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 microg q.i.d. · subcutaneous · 2 weeksAs given in this study (human).
Source sentences
Summary
In addition, 24-h mean plasma glucose concentrations were significantly lowered in patients receiving 30 microg of pramlintide for 2 weeks compared with placebo, while the 100-microg pramlintide dose did not reach statistical significance for the 24-h glucose profiles.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580306
07HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide had no effect on the daily glucose profile versus placebo.
In plain wordsIn patients with IDDM, pramlintide did not change the daily glucose profile compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMean 24-h plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg q.i.d. · subcutaneousAs given in this study (human).
Source sentences
Summary
At 10 microg, pramlintide had no effect on the 24-h glucose profile or on the plasma glucose response to a Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580307
08HumanNon-randomized trialEfficacy outcome
In patients with IDDM, pramlintide had no effect on the test-meal plasma glucose response versus placebo.
In plain wordsIn patients with IDDM, pramlintide did not change blood glucose after the test meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeTest-meal plasma glucose response
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg q.i.d. · subcutaneousAs given in this study (human).
Source sentences
Summary
At 10 microg, pramlintide had no effect on the 24-h glucose profile or on the plasma glucose response to a Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580308
09HumanNon-randomized trialSafety outcome
In patients with IDDM, glucose reductions with pramlintide were not accompanied by increased hypoglycemic events.
In plain wordsIn patients with IDDM, low blood sugar events did not increase at the 30 microg dose of pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycemic events
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
30 microg q.i.d. · subcutaneousAs given in this study (human).
Source sentences
Summary
The reduction in 24-h glucose concentrations and glucose concentrations after the Sustacal test meal observed at the 30-microg pramlintide dose was not accompanied by an increased incidence of hypoglycemic events.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580309
10HumanNon-randomized trialSafety outcome
In patients with IDDM, transient upper gastrointestinal symptoms were the most frequent adverse events and were dose-related.
In plain wordsIn patients with IDDM, temporary upper digestive symptoms were the most frequent side effects and were related to pramlintide dose.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedUpper gastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The most frequent adverse events were dose-related and involved transient upper gastrointestinal symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580310
11HumanNon-randomized trialSafety outcome
In patients with IDDM, most patients reporting pramlintide adverse events in the first week did not report them in the second.
In plain wordsIn patients with IDDM, most first-week side effects with pramlintide were absent in the second week.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePersistence of adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients without repeat adverse events
> 80%
week 2 among patients reporting events in week 1
Source sentences
Summary
A majority (>80%) of the patients who reported these adverse events during week 1 did not report them in week 2.
2 context sentences(design, population, supporting numbers)
Summary · context
The most frequent adverse events were dose-related and involved transient upper gastrointestinal symptoms.
Summary · context
The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial.
Report a problemFND-0907580311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.